Ethylene

Ethylene

SCHEMBL4674338

C=C.CNC1CCC(=O)CC1

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.30
TRIM33 Q9UPN9 1/20 0.30
ESR2 Q92731 1/20 0.30
DRD2 P14416 1/20 0.30
DRD4 P21917 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16752565 0.95 TRIM24 (0.33) TRIM24TRIM33ESR2DRD2DRD4
SCHEMBL561992 0.95
Hydrochloric Acid SCHEMBL26963383 0.92 TRIM24 (0.32) TRIM24TRIM33ESR2DRD2DRD4
SCHEMBL17995298 0.86 TRIM24 (0.39) TRIM24TRIM33ESR2DRD2DRD4
SCHEMBL25608460 0.80
SCHEMBL21997074 0.74
SCHEMBL8342263 0.72 TGM2 (0.33)
Ethylene SCHEMBL977547 0.72 DRD3 (0.41) DRD2DRD4DRD3
SCHEMBL8297545 0.71 SRD5A1 (0.32)
SCHEMBL21047670 0.70 ALDH1A1 (0.38) TRIM24TRIM33ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343503-B1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2008-11-12 EP disclosed
US-7309704-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-18 US disclosed
US-20060030588-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION 2006-02-09 US disclosed
US-6982267-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2006-01-03 US disclosed
US-6946476-B2 For therapy of metabolic and eating disorders such as obesity and hyperphagia, diabetes SCHERING CORPORATION (US) 2005-09-20 US disclosed
EP-1343503-A4 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2004-03-17 EP disclosed
US-20040006086-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists MERCK SHARP & DOHME CORP. 2004-01-08 US disclosed
EP-1343503-A1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS Schering Corporation (US) 2003-09-17 EP disclosed
US-20030055062-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION 2003-03-20 US disclosed
WO-2002049648-A1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055062-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists NPY5R, NPY1R, NPY2R TRIM24 4416/4885TRIM33 4157/4885ESR2 2584/4885
US-20040006086-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists NPY5R, NPY1R, NPY2R TRIM24 4416/4885TRIM33 4157/4885ESR2 2584/4885
US-20060030588-A1 Heteroaryl urea neuropeptide Y Y5 receptor antagonists NPY5R, NPY1R, NPY2R TRIM24 4532/4885TRIM33 4086/4885ESR2 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.